Editorial comment

摘要

Epidermal growth factor receptor (EGFR) is expressed in non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, and breast cancer. In each of these diseases, there are EGFR inhibitors that are approved for these conditions. EGFR is expressed in squamous cell penile cancer. The question: is it potentially useful in patients with squamous cell penile cancer? There are important parameters whether a target for treatment is important or not. Is the target over expressed, could it be inhibited, is it the predominant target, is it an important factor for growth for this cancer, and could it be given safely.